---
document_datetime: 2023-09-21 19:00:42
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/tarceva-epar-all-authorised-presentations_en.pdf
document_name: tarceva-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.633797
conversion_datetime: 2025-12-25 06:40:57.873724
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| EU number                                       | Invented name           | Strength            | Pharmaceutical Form                                         | Route of administration    | Packaging                                             | Package size                     |
|-------------------------------------------------|-------------------------|---------------------|-------------------------------------------------------------|----------------------------|-------------------------------------------------------|----------------------------------|
| EU/1/05/311/001 EU/1/05/311/002 EU/1/05/311/003 | Tarceva Tarceva Tarceva | 25 mg 100 mg 150 mg | Film coated tablets Film coated tablets Film coated tablets | Oral use Oral use Oral use | Blister (PVC/Alu) Blister (PVC/Alu) Blister (PVC/Alu) | 30 tablets 30 tablets 30 tablets |